WHO technical consultation on oxygen scale-up
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
</table>
| 16:00–16:10 | Welcome remarks                                                          | Janet Diaz  
Lead, Clinical Management for COVID-19  
WHO Health Emergency Programme |
Summary of key discussion take-aways from Session 3: Oxygen distribution systems (i.e. piping, cylinders)

✓ Medical Oxygen purity and impurity along the system:
  Lack of guidance with respect to methodology, frequency, and [impurity] parameters.
    o Risk profile for patient impact needs to be assessed.
    o IP for Oxygen 93 needs to be developed, addressing above concerns.

✓ Piping strategy and manifold changeover should remain simple. There are limited experiences to draw off on in LMICs as piping has been seen as a ‘luxury’.

✓ Piping standards have been developed for and are applied in high income countries. They are very stringent, and could be unnecessarily costly, especially where budget constraints abound.

✓ Alternate materials for piping, including polyurethane instead of copper, or “push-fit” instead of welding, are available but the quality and safety has not yet been validated by international standards.

✓ In the practice, it is still difficult to ensure safe and effective cylinder management and use even if general guidance is available.
The aim of this technical consultation is to achieve the following core objectives across four teleworking sessions:

**Needs assessment:** taking stock of existing guidance to forecast oxygen needs; identification of shared challenges; formalizing baseline assumptions and framework methodologies that apply for a high-level oxygen needs estimation for LMICs.

**Technical guidance:** finalizing operational elements and inputs for WHO consideration in producing interim guidance documents for oxygen production from PSA oxygen generator plants and subsequent distribution (e.g. cylinder manifolds, oxygen piping) at the facility level.

**Global scale-up mapping:** establishing live mapping updates and/or networking resources to leverage previous accomplishments, to foster collaborations, and to avoid duplication of activities.

Identification of other work areas could result in the addition of further working sessions.
Mapping activities in the space of scaling up oxygen can serve to optimize our collected efforts and beyond, and ultimately reaching more patients.

Consultation entities have experience in scaling up oxygen access; however, leveraging each other’s experience can be further amplified.

Longer term sustainability will require a holistic approach and an ecosystem of resources; not only focus on oxygen production but distribution and delivery, and ongoing maintenance and upkeep.

While progress has been made, it is believed that the remaining gaps are substantial, but as yet, not quantifiable.

Different approaches to data collection have been taken; however, data utility has not been optimized to illustrate gaps to broader partners in the space.
Efforts in scaling up medical oxygen have been continuously increasing...

Activities and linkages in oxygen scale-up in recent years

➡️ The number of partners have been few; however, many fruitful collaborations resulted.

➡️ Limited donor funding, often geographically specific, and often with country overlaps, was typically linked to paediatric pneumonia.

➡️ Domestic investment in medical oxygen was limited; the medicine often perceived as very expensive.

➡️ The ‘Every Breath Counts’ (EBC) Coalition was established in 2017. It was the first formal platform to integrate medical oxygen as a priority.

Examples of global efforts to capture and manage information

▪ SARA – oxygen availability indicated in a binary output (Y/N), information not publicly available.

▪ HeRAMS – a collaborative approach for sharing information re. essential health resources and services.

▪ EBC: coalition has grown, many linkages happen through this platform / mechanism.
  ▪ Mapping of entities working in the space.
  ▪ Mapping of oxygen-related procurement.

▪ UNICEF: CO Surveys.

▪ Lancet call to build base-line data to inform decision-makers.

These efforts served particular and valid purposes, but still, there is no clear overview of all actions taken for scale-up; there is no clear understanding of existing global capacity.
Example of supplier positioning mapping: PSA plant manufacturers

➔ Rapid market assessment of relevant suppliers in China, Europe and USA market.
➔ 25+ PSA plants manufacturers.
➔ 2 VSA plants manufacturers: PCI, PRISM.
➔ Broad difference with regards quality assurance certifications, lead times and models/configurations.
➔ WHO have not assessed all of them.

<table>
<thead>
<tr>
<th>No.</th>
<th>Supplier</th>
<th>Country</th>
<th>No.</th>
<th>Supplier</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AirSep</td>
<td>USA</td>
<td>14</td>
<td>OGSi</td>
<td>USA</td>
</tr>
<tr>
<td>2</td>
<td>Atlas Copco / BeaconMeades</td>
<td></td>
<td>15</td>
<td>Ox-Air</td>
<td>USA</td>
</tr>
<tr>
<td>3</td>
<td>Can Gas Systems Company Limited</td>
<td>China</td>
<td>16</td>
<td>Oxymat</td>
<td>Slovakia</td>
</tr>
<tr>
<td>4</td>
<td>Chengdu Tcwy New Energy Tech.</td>
<td>China</td>
<td>17</td>
<td>Oxywise</td>
<td>Slovakia</td>
</tr>
<tr>
<td>5</td>
<td>G. Samaras</td>
<td>Greece</td>
<td>18</td>
<td>Özcan Kardeşler</td>
<td>Turkey</td>
</tr>
<tr>
<td>6</td>
<td>Hunan Eter Electronic Medical</td>
<td>China</td>
<td>19</td>
<td>Pneumatech Medical Gas Solution</td>
<td>Germany</td>
</tr>
<tr>
<td>7</td>
<td>Hydrogaz</td>
<td>Poland</td>
<td>20</td>
<td>Sanghi</td>
<td>India</td>
</tr>
<tr>
<td>8</td>
<td>Inmatec</td>
<td>Germany</td>
<td>21</td>
<td>ShanDong MedTech</td>
<td>China</td>
</tr>
<tr>
<td>9</td>
<td>Intakatech</td>
<td>South Africa</td>
<td>22</td>
<td>Suzhou Hengda Purification Equip.</td>
<td>China</td>
</tr>
<tr>
<td>10</td>
<td>Jiangyin Dongpeng Purifying Equip.</td>
<td>China</td>
<td>23</td>
<td>Suzhou HITE Gas</td>
<td>China</td>
</tr>
<tr>
<td>11</td>
<td>Mil’s</td>
<td></td>
<td>24</td>
<td>Sysadvance</td>
<td>Portugal</td>
</tr>
<tr>
<td>12</td>
<td>MVS Engineering</td>
<td>India</td>
<td>25</td>
<td>Tesa Medikal</td>
<td>Turkey</td>
</tr>
<tr>
<td>13</td>
<td>Novair</td>
<td>France</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

There are an increased number of authorized distributors who require a different QA assessment: not only for the products, but to ensure long term service agreements.

List adapted from information shared by CHAI/PATH for use by the GSCC, as of July 10, 2020.
Example of supplier positioning mapping: Global liquid oxygen production

Understanding of where there is product in the market, through a data repository or visualization, will inform the end user of its potential:

➔ 3 companies (Air Liquide, Air Products, Linde) represent most of the market.

➔ These three, along with Gulf Cryo and AirWater, market their product for medical use.

➔ While the mapping is not exhaustive and not representing the in-country reach, it provides a starting point during the strategic planning phase of any medical project.

The liquid market is ripe for engagement; perceived high-costs and no sense of “ownership” have been historical barriers for this segment of the market.

Air Liquide
Air Products & Chemicals
Linde Group
Gulf Cryo
Air Water Inc.
Messer Group
Nippon Gases

Airgas, Messer Group (medical)
Infra, INOX, etc.
Afrox, AGA AB, BOC, MOX-Linde Gases, Praxair, Les Gaz, etc.

Matheson Tri-Gas

List adapted from information shared by CHAI/PATH for use by the GSCC.
Global Medical Oxygen Scale-up Mapping

What could this look like?
Establish a live mapping platform to:
• Centralize a ‘global good’ repository of information and tools.
• Illustrate systems status: full visibility into information and activities.
  o Data sharing only if/where permissible.
• Showcase recent, ongoing, or upcoming activities.
• Leverage previous accomplishments to multiply success.
• Facilitate rapid, standardized, and systematic collection of targeted data sets.

Why would we do this?
• Leverage our collective strengths and foster collaboration.
• Pool our knowledge and avoid duplication.
• Conduct real-time aggregation, analysis, and interpretation of medical oxygen scale-up activities in different contexts.
• Support to shape global, national, and subnational strategies, including policy work and roadmaps.
• Country participation voluntary.
• Potential to increase visibility into a fragmented, opaque market.

Where could we do this?
• WHO has migrated to and proposes REDCap web-based platform, where access is secure, limited, and password-protected.
• WHO has had recent success with the ‘Global WHO COVID-19 Clinical Data Platform’ to inform appropriate clinical interventions, public health response and generation of evidence-based guidelines: https://www.who.int/teams/health-care-readiness-clinical-unit/covid-19/data-platform

WHO is offering to facilitate this initiative to build a Global Data Platform.
Global Medical Oxygen Scale-up Mapping

How can this be done?

1. Define content to be housed on the platform.
2. Develop (or leverage) existing tools, surveys, apps, etc.
3. Ensure accessibility:
   i. Translate all resources to (at least) UN official languages.
   ii. Establish legal parameters, time frame, methods of contribution and use.
   iii. Resource a support network for contributors.
4. Manage and maintain content so that it remains current and relevant.
5. Build out a team for data curation, aggregation, analysis, interpretation.
6. Facilitate information capture both prospectively and retrospectively (to avoid duplication).

Who is this for?

Contributors:
- MoH
- Health facilities
- Clinical/research networks
- NGOs

Users:
- Policy makers
- MoH
- Facilities
- NGOs
- Clinical associations
- Oxygen champions / advocates
- Donors
- Researchers
- Vendors
- Etc.
Detailed steps → Data collection to help determining the gap in availability and accessibility of oxygen

What question(s) do we need answered?

- What is the oxygen availability and accessibility gap?
- Medical equipment inventories
- Facility readiness
- Operational readiness, etc.

Develop survey of data capture needed

- Paper surveys
- ODK / REDCap / SurveyCTO, etc.

Collect data in a systematic manner

- Data consolidation and cleaning

Process the raw data into a usable format

- Adequate staffing for:
  - Operations
  - Tech Support

Analyse data to answer initial questions

Continued capture, systems management

House data in a centralized repository where it will be managed and kept current to reflect real-time situation.
- Leverage existing systems where possible

We are ultimately working at the service of the patient.
The ultimate objective is data-driven action, not a data set unto itself.
<table>
<thead>
<tr>
<th>Country</th>
<th>Partner presence</th>
<th>Country O₂ policy</th>
<th>Activities</th>
<th>Systems integration (e.g. LMIS)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Baseline / gap-analysis</td>
<td>Scale-up strategy/ road-map</td>
</tr>
<tr>
<td>Afghanistan</td>
<td>In-progress</td>
<td></td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Angola</td>
<td>Yes</td>
<td></td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>Yes</td>
<td></td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Benin</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zambia</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Activities can be substantial stand-alone undertakings; however, they are part of the bigger picture.

- Sharing information more broadly can result in collectively closing the gap.
- Leveraging existing systems and resources will support effort of sustainability (e.g. training platforms).
- Activities must be measurable, key indicators targeted at the ultimate objective.
- Partners are often limited for reasons of funding or expertise; however, once the benefit is understood, the multidisciplinary effort can be done.

Note: information herein is for illustrative purposes and does not reflect current country situation.
Discussion on value of Global Medical Oxygen Scale-up Mapping / Data Platform alike to better facilitate safe, reliable, lasting solutions?

Utility
What information could be managed in such a platform to help with scale-up efforts?

Advocacy
Could this type of platform best support advocacy efforts for oxygen scale-up?

Sensitivity
What could be the potential risks for governments to share their data?

Market transparency
• Would public information help merge demand, give visibility, and therefore leverage to the buyer? Would this consolidated information be of benefit the supplier?
• Could some supply perceptions be debunked with greater transparency (e.g. OEM of ‘premium’ brands)?

Are there any additional notable pitfalls?
Are there experiences to share on this regard?

Implementation Technical Advising (TA)
• What additional TA would you expect to be required to support in countries that are underrepresented?
• Could there be value in considering secondments for deployment?

Partner networks
Could this effort further partnerships, strengthen networks and improve coordination across working groups?

Utility
What information could be managed in such a platform to help with scale-up efforts?

Advocacy
Could this type of platform best support advocacy efforts for oxygen scale-up?

Sensitivity
What could be the potential risks for governments to share their data?

Market transparency
• Would public information help merge demand, give visibility, and therefore leverage to the buyer? Would this consolidated information be of benefit the supplier?
• Could some supply perceptions be debunked with greater transparency (e.g. OEM of ‘premium’ brands)?

Are there any additional notable pitfalls?
Are there experiences to share on this regard?

Implementation Technical Advising (TA)
• What additional TA would you expect to be required to support in countries that are underrepresented?
• Could there be value in considering secondments for deployment?

Partner networks
Could this effort further partnerships, strengthen networks and improve coordination across working groups?
Summary of key gaps identified in technical consultation meetings:

**PSA-centric - technical guidance to be developed:**
- system operations, including post-commissioning requirements (3rd party testing).
- preventive and curative maintenance.
- service-level agreement.

**Cylinders - technical guidance to be developed:**
- Maintaining standards (vessel sizes, valve connections, appropriate regulators and flowmeters, etc.).
- Management and use of cylinders in a system/geography.

**Pipelines:**
- Review of international standards for pipelines for medical application.
- Review of guidance for design, installation, validation, and verification of medical gas (oxygen) distribution networks.

**Safety**
- General O₂: Greater need > larger solutions covering continuum: production & distribution & delivery.
- Cylinder handling and safety – need for trainings and better implementation practices.

**Purity:** navigating requirements for medical oxygen there is unclear guidance relating to different sources. What is acceptable in terms of purity and impurities? Why differences among Pharmacopoeias?
**Proposed next steps:**

**ACTION!** Entities are encouraged to:

➔ Review reports from 4 technical consultation meetings (*1 of 4 has been circulated*).

➔ Participate in the development of operational guidance for oxygen systems.

**WHO team currently drafting** *(to be circulated in January 2021 with established timeframes for feedback):*

- PSA strategic planning and procurement.
- PSA system operations, including post-commissioning requirements (3rd party testing).
- PSA preventive and curative maintenance.
- Pipeline technical guidance (distribution network design, including manifold).
- Oxygen 93 monograph (International Pharmacopoeia – *with Essential Medicines Department*).

➔ Participate a forthcoming discussion about the development of a Global Medical Oxygen Scale-up Mapping:

- Consolidated feedback, including the challenges encountered in this session, will be used to further steer the concept.
- In-depth exploration of existing platforms will be carried out for suitability.

➔ Suggest to WHO additional

- Topics for further consultation.
- Bodies of work that would be helpful as a published a Global Good for Medical Oxygen Scale-up.

**THANK YOU!**
Important information

General:
The designations employed within the presentation of materials do not imply the expression of any opinion whatsoever on the part of World Health Organization (WHO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delineation of its boundaries. Where applicable, dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products, by word or image, does not imply endorsement or recommendation by WHO in preference to others of a similar nature that are not otherwise mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

Information Accuracy:
All reasonable precautions have been taken by WHO to verify information contained herein. WHO makes no warranties, express or implied, or representations as to the accuracy and completeness of content. WHO assumes no liability or responsibility for any error or omissions in the information contained in the provided documents. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Confidentiality and Declaration of Interest